{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-05T01:36:55.758Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-05. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-05. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-05, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"RGEN\",\n  \"company\": \"Repligen Corporation\",\n  \"investigation_summary\": \"Repligen is a life sciences bioprocessing tools company with ~$760M TTM revenue growing at ~15% organically. Q1 2026 delivered a +22.9% EPS surprise (beat by $0.09), with 50%+ analytics growth and strong China demand. The stock has been under severe pressure — down ~28% from its January 2026 high of $175.77 to current ~$126 — driven by multiple concerns: tariff uncertainty on biopharma equipment, customer concentration risk, and decelerating monoclonal antibody market growth. However, forward P/E of ~49.7x is expensive for a company with only 8.9% operating margin and 6.7% net margin, leaving limited upside without significant margin expansion. The CEO's tight vote (Karen Dawes/Carrie Eglinton Manner narrowly approved) and Glenn Muir's significant opposition (~25% against) signal governance tension. No open-market insider buys in the past 90 days — all recent Form 4s are equity compensation grants. The stock is below its 200-day MA, creating technical headwinds despite a recent MACD bullish cross.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"cc\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Repligen develops and commercializes bioprocessing technologies used in the manufacture of biologic drugs (monoclonal antibodies, ADCs, cell & gene therapy). Its four product franchises are Filtration/Fluid Management, Chromatography, Process Analytics (PATsmart, ZipChip), and Proteins/ligands. The company serves global biopharma majors, CDMOs, and emerging biotech customers from 19 manufacturing sites across the US, Europe, and Asia-Pacific. Q1 2026 revenue was $194.3M (+14.8% YoY reported; +11% organic); full-year guidance is ~$818M midpoint with non-GAAP EPS ~$2.00. Management launched a 'Transformation Office' targeting manufacturing optimization and IT modernization to accelerate margin expansion, having divested the non-core Polymem business in Q1 2026. The stock fell from $175.77 (Jan 2026) to ~$126 on tariff/customer-concentration concerns but bounced hard off its 52-week low of ~$101.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": null,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-04\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026: +22.9% EPS beat ($0.48 vs $0.39 est); prior quarter Q4 2025: +10.4%; Q3 2025: +10.9%. Consecutive positive surprises over last 4 quarters, trending up.\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 2026 earnings — August 4, 2026. Full-year FY26 EPS guidance of ~$2.00 at midpoint (vs $1.84 prior year). Revenue guide $818M midpoint.\",\n          \"date_or_window\": \"August 4, 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/repligen-rgen-q1-earnings-revenues-131507048.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"Analytics segment growing 50%+ in Q1 2026 — PATsmart and ZipChip products gaining traction. New OEM partnership in China targeting APAC bioprocessing market expansion.\",\n          \"date_or_window\": \"Q1-Q2 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/markets/stocks/articles/repligen-reshapes-operations-china-reach-031805997.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"operational\",\n          \"description\": \"Transformation Office launched to drive manufacturing optimization and margin expansion. Polymem divestiture simplifies portfolio; non-core asset removal may re-rate multiple.\",\n          \"date_or_window\": \"Q1 2026 ongoing\",\n          \"source_urls\": [\n            \"https://www.fool.com/earnings/call-transcripts/2026/05/05/repligen-rgen-q1-2026-earnings-call-transcript/\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 49.71,\n      \"sector_median_forward_pe\": 28,\n      \"ev_to_ebitda\": 52.46,\n      \"sector_median_ev_to_ebitda\": 22,\n      \"fcf_yield_pct\": 0.96,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"RGEN trades at ~49.7x forward P/E vs sector median of ~28x — a significant premium that is only justified if margin expansion materializes from the Transformation Office. The stock has re-rated down sharply (from 175 to 126) but remains priced for perfection on growth. FCF yield of <1% does not support valuation at this multiple.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"A\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": false,\n      \"rsi_14\": 61.3,\n      \"macd_recent_bullish_cross\": true,\n      \"12_1_momentum_vs_sector_pct\": -15\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 126.55,\n    \"ytd_return_pct\": 0.75,\n    \"from_52w_high_pct\": 28\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 revenue ~$763M (+14.8% YoY); gross margin 53%; operating income impacted by restructuring/acquisition costs; $784M cash vs $688M debt; completed Avitide acquisition Apr 2025 for up to $70M; Metenova acquisition Oct 2023 from Sweden\",\n        \"Customer concentration risk disclosed: No single customer >10% in FY2025 (improved from prior years); tariff and supply chain risks explicitly called out as risk factors; convertible senior notes due 2028 ($546M net carrying value)\",\n        \"Transformation initiatives underway including manufacturing optimization, IT modernization, facility rationalization. Polymem business held for sale at Q1 2026\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-06\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/730272/000119312526208954/rgen-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: $194.3M revenue (+14.8% YoY); gross margin ~55.8%; operating income $15.9M; net income $8.3M ($0.48 non-GAAP EPS vs $0.39 est, +24.9% beat); Polymem divestiture loss of $13.76M (non-cash)\",\n        \"Balance sheet: Cash $582.7M, Marketable Securities $201.9M, Total Debt (convertibles) $546.6M; Current ratio 9.2x — fortress balance sheet\",\n        \"Goodwill $1.107B, Intangible assets $368M (from acquisitions); Restructuring charges of $1.5M for facility exits in Q1\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-05-14\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/730272/000119312526225380/rgen-20260514.htm\",\n      \"key_takeaways\": [\n        \"Annual meeting results: Karen Dawes 42.7M for / 9.1M against (19% opposition); Carrie Eglinton Manner similar margin; Glenn Muir received 13.3M against votes (26% opposed) — notable dissent on board/exec compensation\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-02-24\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/730272/000119312526065246/rgen-20260224.htm\",\n      \"key_takeaways\": [\n        \"Q4 2025 earnings: EPS $0.49 vs $0.44 est (+10.4%); full FY2026 guidance issued, Transformation Office announced\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-08-21\",\n      \"2026-07-17\",\n      \"2026-06-18\"\n    ],\n    \"iv_summary\": \"ATM IV at Aug 2026 expiry is ~54-56%. Elevated but not extreme for a mid-cap biotech-adjacent name. Calls more active than puts (net +$330K directional bias). Top OI call strike at $125 (1723 contracts) vs spot $126.55 — essentially ATM; put OI concentrated at $120 and $95.\",\n    \"notable_skew_or_flow\": \"Modestly bullish flow with 419-contract whale block in the $125 Aug21 calls ($599K notional), suggesting someone is positioning for an upside move ahead of earnings on Aug 4. Put/call ratio of 0.47 (bullish lean). V/OI ratio on most strikes <1, indicating no dramatic new speculative positions.\"\n  },\n  \"competitive_landscape\": \"Repligen competes with Sartorius AG, Danaher (Cytiva/Pall), Thermo Fisher Scientific, and MilliporeSigma in the $30B+ bioprocessing equipment market. RGEN's niche is hollow-fiber filtration, PAT/analytics tools, and Protein A ligands — more specialized than its larger competitors. The company competes on product differentiation and customer intimacy rather than scale. Its valuation premium (EV/EBITDA 52x vs sector ~22x) reflects the analytics/new modalities growth story.\",\n  \"key_risks\": [\n    \"Valuation extremely expensive at 49.7x forward P/E for a company with low margins — any deceleration in growth will compress multiples severely\",\n    \"Tariff risk on US-manufactured bioprocessing equipment; management explicitly called out import/export restrictions and trade policy as risk factors\",\n    \"Customer concentration has improved (no single customer >10%) but large biopharma customers wield significant pricing leverage during contract renewals\",\n    \"Large goodwill balance ($1.1B) creates impairment risk if growth assumptions don't materialize; acquisitions have not yet been fully integrated\",\n    \"Below 200-day MA — technical headwinds could suppress upside even on positive news\"\n  ],\n  \"what_the_market_might_be_missing\": \"The market appears to be anchoring on the stock's decline from $175 (tariff fears, macro concerns) without giving enough credit to: (1) consecutive strong earnings beats (+22.9% last quarter), (2) 50%+ analytics segment growth representing a genuine shift in product mix toward higher-value offerings, and (3) China OEM partnership expanding APAC addressable market at a time when Chinese biopharma is rapidly building domestic biologics manufacturing capacity. The Transformation Office margin expansion program is underappreciated — if operating margins can expand from 8.9% to low-teens over the next 18-24 months, the forward multiple compresses meaningfully without any growth acceleration. However, this remains a thesis that requires execution evidence and is not yet confirmed.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"accounting\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"10-K FY2025\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm\"\n    },\n    {\n      \"label\": \"10-Q Q1 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/730272/000119312526208954/rgen-20260331.htm\"\n    },\n    {\n      \"label\": \"Q1 Earnings Beat\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/repligen-rgen-q1-earnings-revenues-131507048.html\"\n    },\n    {\n      \"label\": \"Transformation Office + China Partnership\",\n      \"url\": \"https://finance.yahoo.com/markets/stocks/articles/repligen-reshapes-operations-china-reach-031805997.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-05T01:37:57.288Z",
      "raw_content": "<think>The dossier is for RGEN (Repligen Corporation).\nLet's score it according to the rubric.\n\nA. SMART-MONEY CLUSTER (max 25)\n- Insider open market purchases 90d: 0. (0 pts)\n- 13F holders: pending. (0 pts)\n- Anti-signal: dilution (convertible notes $546M), accounting (Polymem divestiture loss, restructuring charges, but not restatements). Wait, anti_signals_present says \"dilution\" and \"accounting\". I need to check if these are hard gates.\nDilution gate: \"Convertible/warrant overhang creating dilution > 10% of float\". Convertible senior notes due 2028 ($546M net carrying value). Float is roughly 126 * ~30M shares = ~$3.7B. $546M is ~15% of market cap, likely >10% of float. This triggers the anti-signal gate.\nAccounting gate: \"Accounting irregularities (restatements, auditor changes)\". The dossier mentions \"Polymem divestiture loss of $13.76M (non-cash)\" and restructuring charges. Not necessarily irregularities, but the anti-signal list says \"accounting\". I will treat it as a caution but maybe not a hard gate unless it's restatements. However, the prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nDilution > 10% of float: Convertible notes $546M. Float ~30M shares * $126 = $3.78B. $546M / $3.78B = 14.4%. This triggers the dilution gate.\nI will skip due to anti-signal gates (dilution > 10% of float, and lack of insider buying + expensive valuation).\n\nLet's compute scores anyway to be thorough, but the anti-signal gate forces a skip.\nA. Smart Money: 0\nB. Options Flow: 4 pts (whale_call_blocks_otm ≥ 2? Dossier says \"419-contract whale block in the $125 Aug21 calls ($599K notional)\". That's 1 block. Maybe not ≥2. But let's give 2 pts for call bias. Actually, dossier says \"net +$330K directional bias\". I'll give 2 pts.)\nC. Catalyst: 10 pts (earnings within 90 days AND last 4 quarters' EPS surprise > 0%). Dossier confirms Q1 2026 beat, prior 3 quarters beat. So 10 pts.\nD. Mispricing: 0 pts. Forward P/E 49.7 vs sector 28. EV/EBITDA 52.4 vs 22. FCF yield 0.96%. All expensive.\nE. Quality: 0 pts. ROIC null, gross margin trend null, net debt/EBITDA null. Balance sheet grade A but no metrics.\nF. Technical: 3 pts (above 50DMA). Below 200DMA. RSI 61.3. MACD cross. So 3+1 = 4 pts.\nTotal Score: ~16 pts. Well below 45.\n\nAnti-signal gates: \"dilution\" and \"accounting\".\nDilution gate: \"Convertible/warrant overhang creating dilution > 10% of float\". Convertible notes $546M. Float ~30M shares * $126 = ~$3.8B. 14% > 10%. Gate triggered.\nAccounting gate: \"Accounting irregularities (restatements, auditor changes)\". Dossier mentions divestiture loss and restructuring, but not restatements. I'll note it doesn't strictly apply as irregularities, but dilution does.\nAlso, valuation is extremely expensive (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield). No mispricing.\nVerdict is range_bound_or_income, but with no insider buying, expensive valuation, and dilution overhang, there's no good income structure either (IV is 54-56%, elevated, but selling calls on an expensive stock with dilution overhang is risky; selling puts implies owning at $120, but the thesis is weak).\nThe prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will articulate that the dilution gate is real (convertible notes >10% of float) and the valuation is stretched, making it a skip.\n\nLet's draft the skip JSON.\nScore breakdown:\nsmart_money: 0\noptions_flow: 2\ncatalyst: 10\nmispricing: 0\nquality: 0\ntechnical: 4\nTotal: 16\n\nReason: Anti-signal gate triggered for convertible dilution (>10% of float) and no insider buying. Valuation is severely stretched (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) with no margin of safety. Despite an upcoming earnings beat, the risk/reward is poor for both equity and income structures.\n\nCheck dates: 2026-06-05. Earnings 2026-08-04. All good.\nCheck structure: Skip JSON format.\nAll constraints met.\nProceed. \nLet's double check the anti-signal gate wording: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will articulate why \"accounting\" doesn't apply (it's a non-cash divestiture loss/restructuring, not irregularities), but \"dilution\" does apply (convertible notes $546M > 10% of ~$3.8B float). Given the stretched valuation and lack of catalyst for multiple expansion, I skip.\nScore is low anyway.\nOutput matches format.\nDone. \nOne minor thing: The prompt says \"skip unless you can articulate WHY it doesn't apply to this case.\" I will state that clearly.\nReady. \nOutput JSON. \n{\n  \"skip\": true,\n  \"score\": 16,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Anti-signal gate triggered for convertible dilution (>10% of float) and no insider buying. Valuation is severely stretched (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) with no margin of safety. Despite consecutive earnings beats, the risk/reward is poor for both equity and income structures.\"\n}\nMatches requirements. No extra text. Valid JSON.\nProceeds. \nSelf-Correction/Verification during thought:\nCheck dilution gate math: Convertible notes $546M. Float ~30M shares * $126 = $3.78B. 546/3780 = 14.4%. >10%. Gate triggers.\nCheck accounting gate: \"Accounting irregularities (restatements, auditor changes)\". Dossier says \"Polymem divestiture loss of $13.76M (non-cash)\" and restructuring. Not irregularities. I will note this distinction but the dilution gate stands.\nScore breakdown sums to 16.\nAll good.\nOutput matches exactly. \nProceeds. \n[Output Generation] -> JSON only. \n(Note: I will ensure the JSON is strictly valid and matches the requested schema exactly.)\nAll constraints checked. Date rules respected (none used in skip, but earnings date 2026-08-04 is in dossier). \nReady. \nOutput matches response. \nProceeds. \n[Final Check of the Prompt]\n\"IF YOU SKIP — output exactly: { \"skip\": true, \"score\": <0-100 composite>, \"score_breakdown\": {...}, \"reason\": \"...\" }\"\nMatches.\nDone. \nOutput Generation. \n```json\n{\n  \"skip\": true,\n  \"score\": 16,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Anti-signal gate triggered for convertible dilution (>10% of float). The 'accounting' flag refers to non-cash divestiture/restructuring charges, not irregularities, but the dilution overhang ($546M notes) combined with severely stretched valuation (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) and zero insider buying makes this a skip. No margin of safety exists for equity or income structures.\"\n}\n```\nWait, the prompt says \"output exactly:\" and then shows the JSON structure. I will output just the JSON without markdown fences as requested (\"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\").\nAll good. \nProceeds. \n[Output Generation] (matches the final block)\nDone. \n(Self-Correction/Refinement during thought)\nI should make sure the score breakdown keys match exactly: \"smart_money\", \"options_flow\", \"catalyst\", \"mispricing\", \"quality\", \"technical\".\nYes.\nScore: 16.\nReason: concise.\nReady. \nOutput matches. \n[Proceeds]\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 16,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Anti-signal gate triggered for convertible dilution (>10% of float). The 'accounting' flag refers to non-cash divestiture/restructuring charges, not irregularities, but the dilution overhang ($546M notes) combined with severely stretched valuation (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) and zero insider buying makes this a skip. No margin of safety exists for equity or income structures.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 16,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Anti-signal gate triggered for convertible dilution (>10% of float). The 'accounting' flag refers to non-cash divestiture/restructuring charges, not irregularities, but the dilution overhang ($546M notes) combined with severely stretched valuation (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) and zero insider buying makes this a skip. No margin of safety exists for equity or income structures.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 16,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 4\n  },\n  \"reason\": \"Anti-signal gate triggered for convertible dilution (>10% of float). The 'accounting' flag refers to non-cash divestiture/restructuring charges, not irregularities, but the dilution overhang ($546M notes) combined with severely stretched valuation (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) and zero insider buying makes this a skip. No margin of safety exists for equity or income structures.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 61530,
  "stop_reason": "stop",
  "completed_at": "2026-06-05T01:37:57.288Z"
}